Generex Oncology Announces Consultancy Of Dr. George E. Peoples, MD
WORCESTER, Mass., Sept. 2, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (Nasdaq:GNBT) today announced the engagement of Dr. George E. Peoples, Jr., M.D., F.A.C.S. as a consultant to the Company in respect of the on-going clinical and regulatory work of Antigen Express, Inc. ( www.antigenexpress.com ), the Company's wholly-owned subsidiary, in respect of the proprietary Antigen Express AE37 immunotherapeutic breast cancer vaccine, presently in a Phase II clinical trial at The Henry M. Jackson Foundation for the Advancement of Military Medicine ( www.hjf.org ).
Dr. Peoples is presently the Chief of Surgical Oncology at Brooke Army Medical Center in Houston, TX, a Professor of Surgery and the Director & Principal Investigator of the Cancer Vaccine Development Program at Uniformed Services University of the Health Sciences in Bethesda, MD, and the Deputy Director of the United States Military Cancer Institute ( www.usmci.org ). Dr. Peoples is a graduate of Johns Hopkins University School of Medicine.
During his career, Dr. Peoples has authored over 100 papers in peer-reviewed journals and conducted numerous clinical studies of peptide vaccines. As such, he is uniquely qualified to help guide the success of AE37. Pursuant to the consultancy arrangement, Dr. Peoples will supervise the on-going Phase II clinical trial of the Company's breast cancer vaccine, provide advice and assistance to the Company in respect of the design and implementation of a Phase III trial of the vaccine, and liaise with the Food and Drug Administration regarding the clinical and regulatory development of the vaccine. "We are very fortunate to have the assistance of Dr. Peoples in the development of AE37," said Dr. Eric von Hofe, President of Antigen Express. "There are few people with his experience and insight into the development of active immunotherapy for cancer."
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV